Introduction
T he recent introduction of oral direct acting antivirals (DAAs) has rapidly changed the current clinical approach in chronic hepatitis C (CHC) treatment 1 with higher rates of sustained virological response (SVR) and absence of significant side-effects. 2 However the high costs of these drugs lead to unavailability of the interferon (IFN)-free therapies especially in developing countries or in limited resources settings. 3 In Italy, the Italian Drug Agency (AIFA) reserved the IFN-free regimens only for patients with severe hepatic fibrosis or cirrhosis, whereas for patients with genotype 1 (GT1) or GT4 infection with Metavir F0-F2 the available treatment consists in a IFN-based therapy with pegylated (PEG)-IFN, ribavirin (RBV) and simeprevir; however, only a few subject choose this option for the well-known side-effects of PEG-IFN. Other patients with GT2 or GT3 and Metavir F0-F2 the only available option is the standard dual therapy with PEG-IFN and RBV for 24 weeks. Though this treatment was effective in naïve patients, 4 the PEG-IFN administration is contraindicated in special population, requires a good adherence and frequent blood examinations and the most common side-effects can lead to worsening in life and job conditions, with high rate of treatment interruption 5 ; for these reasons, the choice of this treatment is currently discouraged due to waiting for IFN-free regimens.
In this study, we evaluated the reasons related to treatment acceptance or refusal in a perspective cohort of naïve patients with GT2/3 and F0.F2 Metavir score in the era of DAAs.
Methods

Study design
This prospective, observational, single-centre, study was performed at our hospital 'Amedeo di Savoia', Turin, Italy, between January 2014 and June 2015. The study protocol was approved by our local Ethic Committee. Patients given written informed consent. Epidemiological, social and clinical data of patients were collected in medical records; reasons for treatment acceptance or refusal were recorded through a questionnaire. Inclusion criteria were: naïve patients with CHC and GT2/3, fibrosis stage F0-F2.
Exclusion criteria were: previously treated patients, other genotypes, fibrosis stage >F2, major contraindications for PEG-IFN and RBV.
Fibrosis stage was evaluated as METAVIR Fibrosis Score using transient elastography (Fibroscan, Echosens, Paris, France); according to liver stiffness cut-off values reported in Castéra et al. 
Statistical analysis
In descriptive statistics continuous variables were summarized as median [Inter-quartile range (IQR): 25th-75th percentiles). 
Results
Study population
During the evaluation period, a total of 226 patients with GT2/3 CHC were screened at our institute; among these patients, 66 were excluded for the fibrosis stage >F2 and 28 for previous treatment with PEG-IFN and RBV; finally, 132 patients were included in the study: 34 with GT2 and 98 with GT3 (figure 1). Baseline patients characteristics were reported in table 1. Significant differences in clinical, epidemiological and social conditions were detected between GT2 and GT3 patients. Patients with GT3 were younger, with prevalent sex male and mostly with i.v. drug use (IDU) as risk factor for HCV infection. Other clinical findings most frequent in GT3 were: cryoglobulinemia, insulinresistance, diabetes. 41 GT3 patients were active IDU and 34 taking methadone or buprenorphine therapy. Unemployed patients were prevalent in GT2, whereas homeless and living alone in GT3.
Treatment decision
A total of 53 patients accepted the treatment option with PEG-IFN and RBV (40.1%): 12 with GT2 (22%) and 41 GT3 (41.8%) (P < 0.001).
In 79 patients, treatment was refused or delayed (59.8%): 22 with GT2 (64.7%) and 57 with GT3 (58.2) (P < 0.001) ( figure 2A) .
Treatment decision analysis was classified between 'patients' conditions', including all social, economics, personal and behavioural conditions referred to clinicians and 'clinical conditions', including clinical data documented by physicians.
As showed in figure 2B , clinical conditions were the main causes of treatment delay (67%) in GT2 patients; among these, the low fibrosis stage and the age > 60 years were the more frequent reasons. In GT3 patients, conversely, patients' conditions were strongly related to treatment refusal (96%). Table 2 were reported in detail all reasons for treatment refusal or acceptance; in GT2 patients fear of PEG-IFN side-effects was the only cause of refusal related to the will of patients; in GT3 social, work, family and behavioural aspects were prevalent. Low fibrosis stage and age > 60 years were the most important reasons for treatment refusal in GT2 patients. In GT3 most important reasons to accept treatment were the wish to eradicate the infection, the desire of plan the pregnancy for female patients and other familylife conditions; clinical conditions, such as extrahepatic manifestations, were prevalent in GT2 patients.
These factors were examined in univariate and multivariate analysis: fear of PEG-IFN side-effects was the only predictive factor of treatment refusal in GT2 patients (OR = 2.211; 95% CI = 1.117-4.551; P < 0.001). In GT3 patients predictive factors were: fear of side-effects (OR = 1.774; 95% CI = 1.089-2.117; P = 0.016) and active alcoholism (OR = 1.144; 95% CI = 1.012-2.006; P = 0.025). For treatment acceptance predictive factors were the presence of extrahepatic manifestations (OR = 1.911; 95% CI = 1.124-2.912; P = 0.019) in GT2 and the will to eradicate the infection (OR = 2.140; 95% CI = 1.120-3.445; P = 0.008) in GT3 patients.
Discussion
The approach of treatment in CHC is rapidly changing after the introduction of novel DAAs; the IFN-free regimens are most effective and tolerable than the IFN-based treatment, but in some cases are currently not available due to higher costs. However, in a defined group of patients, dual therapy might still be used with acceptable effectiveness in countries where DAAs are not dispensed for all patients. 7 For example, in Italy, the IFN-free treatments are provided only in patients with severe fibrosis or cirrhosis, whereas GT2/3 patients with F0-F2 can only choose between standard dual therapy with PEG-IFN and RBV or waiting for new therapies when available. In this study, we evaluated the reasons for treatment refusal or acceptance in a population with favorable genotypes, low fibrosis stage and without previous treatment; the global rate of treatment acceptance was 40%, similar to that reported by Niederau et al. 8 for GT2/3 patients (40.6%). This is a first interesting point of discussion, because it demonstrates that in the 'DAAs era' the IFN-based regimens still remain a reliable alternative in patients who are not eligible for IFN-free treatments. In our study, however, the treatment rates were significantly higher in GT3 than GT2 patients (41.8 vs. 22%) and this is probably related to the different characteristics in the two groups: GT2 patients were older than GT3 ones and for this reason, despite the expected SVR higher chance, both clinicians and patients avoid treatment, also considering the lower tolerance to PEG-IFN and the problems related to s.c. administration in older subjects. On the other hand, GT2 patients with <65 years accepted the treatment option considering the physicians advice about higher chance of SVR or the presence of extrahepatic manifestations that would be improved after therapy. The group of GT3 patients showed significant differences in demographic data (the median age was 20 years lower than in GT2), epidemiological and behavioural characteristics: active IDU and alcoholism (41.8 and 17.3%, respectively) were related to poor adherence, increase of side-effects and lower tolerance to PEG-IFN, but more often these were conditions associated to social disadvantage and difficult living conditions (homeless or living alone patients). In these cases, the clinicians' decision prevailed to avoid the PEG-IFN treatment, encouraging the patients to undertake the substitution therapy with methadone or buprenorphine or disulfiram in association to psychological support and social assistance. The concomitant conditions of drug abuse and other social problems were related to lower treatment rate in previous studies, 9 despite the observed similar SVR. 10 For other patients with difficult living conditions (for unemployment or previous imprisonment), main problems were the storage of PEG-IFN in absence of refrigerator and the frequent moves to hospital for blood tests. On the other side, GT3 patients without these conditions were strongly motivated to accept the treatment and they were well informed about the features of this therapy. Younger female patients wanted to eradicate the infection before planning pregnancy and also in other subjects the wish of viral eradication was strictly related to improvement of family life conditions or professional work.
This study has some limitations: first, the selection bias of patients with only GT2/3 and lower fibrosis stage is related to current available therapies in Italy, where patients with advanced fibrosis or cirrhosis are eligible for more desirable IFN-free regimens; second, the described observations will probably change soon with future extension of novel therapies without IFN also in patients without severe hepatic fibrosis.
Nevertheless, this study provides an actual information about the characteristics of patients excluded from the IFN-free regimens and potentially suitable for standard therapy, but the older age and lower fibrosis score were the most important factors associated to treatment refusal in GT2 patients, and the behavioural and social condition in GT3; however, dual therapy continues to have an important role when patients were strongly motivated and aware of the advantages arising from viral eradication.
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Key points
IFN free therapies were currently not available for all patients; the standard dual therapy remains the only option for patients with GT2/3 and lower fibrosis stage in Italy. The decision of treatment refusal or acceptance is related both to clinical and patients conditions. A global low rate of treatment decision should not discourage the use of PEG-IFN when patients were young, with strong motivation and higher chance of benefit from viral eradication. ns, non-significant.
